長長崎大学大学院医歯薬学総合研究科 医療科学専攻 分子硬組織生物学分野

ENGLISH

業　績

研究業績
（長崎大学赴任以降2008年～）

  1. Jiang Q, Qin X, Nagano K, Komori H, Matsuo Y, Taniuchi I, Ito K, Komori T
    Different requirements of Cbfb and Runx2 in skeletal development among calvaria, limbs, vertebrae and ribs.
    International Journal of Molecular Sciences 23(21), 13299 (2022)

  2. Matsubara T, Iga T, Sugiura Y, Kusumoto D, Sanosaka T, Tai-Nagara I, Takeda N, Fong GH, Ito K, Ema M, Okano H, Kohyama J, Suematsu M, Kubota M.
    Coupling of angiogenesis and odontogenesis orchestrates tooth mineralization in mice. Journal of Experimental Medicine 219 (4), e20211789 (2022)

  3. Date Y, Taniuchi I, Ito K*
    Oncogenic Runx1–Myc axis in p53-deficient thymic lymphoma.
    Gene 819, 146234 (2022)

  4. Otani S, Date Y, Ueno T, Ito T, Kajikawa S, Omori K, Taniuchi I, Umeda M, Komori T, Toguchida J, Ito K*. 
    Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma.
    Oncogene 41(5), 683-691 (2022)

  5. Qin X, Jiang Q, Komori H, Sakane C, Fukuyama R, Matsuo Y, Ito K, Miyazaki T, Komori T. 
    Runt-related transcription factor-2 (Runx2) is required for bone matrix protein gene expression in committed osteoblasts in mice.
    Journal of Bone and Mineral Research 36(10), 2081-2095 (2021)

  6. Yoshioka K, Nagahisa H, Miura F, Araki H, Kamei Y, Kitajima Y, Seko D, Nogami J, Tsuchiya Y, Okazaki N, Yonekura A, Ohba S, Sumita Y, Chiba K, Ito K, Asahina I, Ogawa Y, Ito T, Ohkawa Y, Ono Y.　
    Hoxa10 mediates positional memory to govern stem cell function in adult skeletal muscle.
    Science Advances 7(24): eabd7924 (2021)

  7. Qin X, Jiang Q, Nagano K, Moriishi T, Miyazaki T, Komori H, Ito K, von der Mark K, Sakane C, Kaneko H, Komori T. 
    Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts.
    PLOS Genetics 16(11): e1009169 (2020)

  8. Date Y, Ito K*
    Oncogenic RUNX3: A link between p53 deficiency and MYC dysregulation
    Molecules and Cells 43(2), 176-181 (2020)

  9. Kageyama S, Ii H, Taniguchi K, Kubota S, Yoshida T, Isono T, Chano T, Yoshiya T, Ito K, Yoshiki T, Kawauchi A, Nakata S.
    Mechanisms of Tumor Growth Inhibition by Depletion of γ-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy.
    International Journal of Molecular Sciences 19(7), 2054 (2018)

  10. Ii H, Yoshiya T, Nakata S, Taniguchi K, Hidaka K, Tsuda S, Mochizuki M, Nishiuchi Y, Tsuda Y, Ito K, Kageyama S, Yoshiki T.
    A novel prodrug of a γ-Glutamylcyclotransferase inhibitor suppresses cancer cell proliferation in vitro and inhibits tumor growth in a xenograft mouse model of prostate cancer.  ChemMedChem 13, 155-163 (2018)

  11. Uekawa A, Yamanaka H, Lieben L, Kimira Y, Uehara M, Yamamoto Y, Kato S, Ito K, Carmeliet G, Masuyama R.
    Phosphate-dependent luminal ATP metabolism regulates transcellular calcium transport in intestinal epithelial cells.
    FASEB Journal 32, 1903-1915 (2018)

  12. Morita K, Suzuki K, Maeda S, Matsuo A, Mitsuda Y, Tokushige C, Kashiwazaki G, Taniguchi J, Maeda R, Noura M, Hirata M, Kataoka T, Yano A, Yamada Y, Kiyose H, Tokumasu M, Matsuo H, Tanaka S, Okuno Y, Muto M, Naka K, Ito K, Kitamura T, Kaneda Y, Liu PP, Bando T, Adachi S, Sugiyama H, Kamikubo Y.
    Genetic regulation of the RUNX transcription factor family has antitumor effects
    Journal of Clinical Investigation 127, 2815-2828 (2017)

  13. Chuang LSH, Ito K, Ito Y. 
    Roles of RUNX in solid tumors.
    Advances in Experimental Medicine and Biology 962, 299-320 (2017)

  14. Jiang Q, Qin X, Kawane T, Komori H, Matsuo Y, Taniuchi I, Ito K, Izumi S, Komori T. 
    Cbfb2 isoform dominates more potent Cbfb1 and is required for skeletal development. Journal of Bone and Mineral Research 31(7), 1391-1404 (2016)

  15. Nagatake T Fukuyama S, Sato S, Okura H, Tachibana M, Taniuchi I, Ito K, Shimojou M, Matsumoto N, Suzuki H, Kunisawa J, Kiyono H. 
    Central role of core binding factor 2 in mucosa-associated lymphoid tissue organogenesis in mouse.
    PLOS ONE 10(5): e0127460 (2015)

  16. Qin X, Jiang Q, Matsuo Y, Kawane T, Komori H, Moriishi T, Taniuchi I, Ito K, Kawai Y, Rokutanda S, Izumi S, Komori T. 
    Cbfb regulates bone development by stabilizing Runx family proteins. 
    Journal of Bone and Mineral Research 30 (4), 706-714 (2015).

  17. Ju X, Ishikawa T, Naka K, Ito K, Ito Y, Oshima M. 
    Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. 
    Cancer Science 105, 418-424 (2014)

  18. Ito K, Maruyama Z, Sakai A, Izumi S, Moriishi T, Yoshida CA, Miyazaki T, Komori H, Takada K, Kawaguchi H, Komori T. 
    Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation. 
    Oncogene 33, 1862-1871 (2014)

  19. Tsang YHN, Wu XW, Lim JS, Ong CW, Salto-Tellez M, Ito K, Ito Y, Chen LF.
    Prolyl isomerase Pin1 down-regulates tumor suppressor RUNX3 in breast cancer.  Oncogene 32, 1488-1496 (2013)

  20. Chuang LSH, Ito K, Ito Y.
    RUNX family: Regulation and diversification of roles through interacting proteins.  International Journal of Cancer 132, 1260-1271 (2013)

  21. Ito K.
    Tumor suppressive functions of RUNX3 in gastric carcinogenesis
    Seikagaku, 84(4), 278–282 (2012)

  22. Voon DC, Wang H, Koo JK, Nguyen TA, Hor YT, Chu YS, Ito K, Fukamachi H, Chan SL, Thiery JP, Ito Y. 
    Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity.　
    Stem Cells 30, 2088-2099 (2012)

  23. Omar MF, Ito K, Nga ME, Soo R, Peh BK, Ismail TM, Thakkar B, Soong R, Ito Y. Salto-Tellez M.
    RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status.
    Pathology & Oncology Research 18, 783-792 (2012)

  24. Ohyama K, Shiokawa A, Ito K, Masuyama R, Ichibangase T, Kishikawa N, Imai K, Kuroda N.
    Toxicoproteomic analysis of a mouse model of nonsteroidal anti-inflammatory drug-induced gastric ulcers.
    Biochem. Biophys. Res. Commun.420, 210-215 (2012)

  25. Nakazawa Y, Sasaki K, Mitsutake N, Matsuse M, Shimada M, Nardo T, Takahashi Y, Ohyama K, Ito K, Mishima H, Nomura M, Kinoshita A, Ono S, Takenaka K, Masuyama R, Kudo T, Slor H, Utani A, Tateishi S, Yamashita S, Stefanini M, Lehmann A, Yoshiura K, Ogi T.
    Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide excision repair.
    Nature Genetics 44, 586-592 (2012)

  26. Huang B, Qu Z, Ong CW, Tsang YHN, Xiao G, Shapiro D, Salto-Tellez M, Ito K*, Ito Y, Chen LF*. 
    RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α. Oncogene 31, 527-534 (2012)

  27. Satoshi Fujii, Katsumi Fukamachi, Hiroyuki Tsuda, Ito K, Yoshiaki Ito, Atsushi Ochiai. 
    RAS oncogenic signal upregulates EZH2 in pancreatic cancer. 
    Biochem. Biophys. Res. Commun. 417, 1074-1079 (2012)

  28. Sugai M, Aoki K, Osato M, Nambu Y, Ito K, Taketo MM, Shimizu A. 
    Runx3 is required for full activation of regulatory T cells to prevent colitis-associated tumor formation.
    Journal of immunology 186, 6515-6520 (2011)

  29. Fukamachi H, Shimada S, Ito K, Ito Y, Yuasa Y.
    CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation.
    Cancer Science 102, 1313-1321 (2011).

  30. Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, Ochiai A. 
    MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
    Oncogene 30, 4118-4128 (2011).

  31. Ito K. 
    RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers.
    Journal of Cellular Biochemistry 112, 1243-1249 (2011)

  32. Ito K, Chuang LSH, Ito T, Chang TL, Fukamachi H, Salto-Tellez M, Ito Y.
    Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology 140, 1536-1546 (2011)

  33. Mikasa M, Rokutanda S, Komori H, Ito K, Tsang YS, Date Y, Yoshida CA, Komori T.  Regulation of Tcf7 by Runx2 in chondrocyte maturation and proliferation.
    Journal of Bone and Mineral Metabolism 29, 291-299 (2011)

  34. Subramaniam MM, Chan JY, Omar MFM, Ito K, Ito Y, Yeoh KG, Salto-Tellez, M, Putti TC.
    Lack of RUNX3 inactivation in columnar cell lesions of breast.
    Histopathology 57, 555-563 (2010)

  35. Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T, Ida H, Ito K, Chiba T, Ito Y, Otsuji E.
    RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
    Anticancer Research 30, 2673-2682 (2010)

  36. Suzuki M, Suzuki H, Minegishi Y, Ito K, Nishizawa T, Hibi T.
    H. pylori-Eradication Therapy Increases RUNX3 Expression in the Glandular Epithelial Cells in Enlarged-Fold Gastritis. 
    Journal of Clinical Biochemistry and Nutrition 46, 259-264 (2010)

  37. YHN Tsang, A Lamb, J Romero-Gallo, B Huang, Ito K, RM Peek Jr, Y Ito and LF Chen.  Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation.
    Oncogene 29, 5643-5650 (2010)

  38. Lee CWL, Ito K, Ito Y. 
    Role of RUNX3 in bone morphogenic protein signalling in colorectal cancer.
    Cancer Research 70, 4243-4252 (2010)

  39. Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, Wee H, Lee HW, Hosoya A, Chung JH, Jang JJ, Kundu JK, Surh YJ, Kim WJ, Ito Y, Jung HS, Bae SC. 
    Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer.  Oncogene 29, 3349-3361 (2010)

  40. Chang TL, Ito K*, Ko TK, Liu Q, Yang S, Salto-Tellez M, Yeoh KG, Fukamachi H, Ito Y*.  Claudin-1 has tumor suppressive activity and is a direct target ofRUNX3in gastric epithelial cells. 
    Gastroenterology 138, 255-265 (2010)

  41. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K*, Salto-Tellez M*.
    Molecular Pathology of RUNX3 in Human Carcinogenesis.
    Biochimica et Biophysica Acta (BBA) Reviews on Cancer 1796, 315-331 (2009)

  42. Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y.
    Quantitative Analysis of Tumor-derived Methylated RUNX3 Sequences in the Serum of Gastric Cancer Patients.
    Anticancer Research 29, 2619-2625 (2009)

  43. Ito K, Inoue K, Bae SC, Ito Y. 
    Runx3 expression in gastrointestinal tract epithelium: resolving the controversy.
    Oncogene 28, 1379-1384 (2009)

  44. Subramaniam MM, Chan JY, Soong R, Ito K, Yeoh KG, Wong R, Guenther T, Will O, Chen CL, Kumarasinghe MP, Ito Y, Salto-Tellez M.
    RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis.
    American Journal of Gastroenterology 104, 426-436 (2009)

  45. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. 　RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. 
    Breast Cancer Res. Treat. 113, 113-121 (2009)

  46. Ogasawara N, Tsukamoto T, Mizoshita T, Inada KI, Ban H, Kondo S, Takasu S, Ushijima T, Ito K, Ito Y, Ichinose M, Ogawa T, Joh T, and Tatematsu M. 
    RUNX3 expression correlates with chief cell differentiation in human gastric cancers. 
    Histology and Histopathology 24, 31-40 (2009)

  47. Pande S, Ali SA, Dowdy C, Zaidi SK, Ito K, Ito Y, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 
    Subnuclear targeting of the Runx3 tumor suppressor and its epigenetic association with mitotic chromosomes. 
    J. Cell. Physiol. 218, 473-479 (2008)

  48. Ito K, Lim A, Salto-Tellez M, Motoda L, Osato M, Chuang L, Lee C, Voon D, Koo J, Wang H, Fukamachi H, Ito Y.
    RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigeneisis.
    Cancer Cell14, 226-237 (2008)

  49. Fujii S, Ito K, Ito Y, and Ochiai A.  Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation and in synergism with DNA methylation.
    J. Biol. Chem. 283, 17324-17332 (2008)

  50. Sakuma A, Fukamachi H, Ito K, Ito Y, Takeuchi S, Takahashi S. 
    Loss of Runx3 affects ovulation and estrogen-induced endometrial cell proliferation in female mice. 
    Mol. Reprod. Dev. 75, 1653-1661 (2008)

  51. Müller CI, Luong QT, Shih LY, Jones LC, Desmond JC, Kawamata N, Tcherniantchouk O, Liu Q, Ito K, Osato M, Ito Y, Tefferi A, de Vos S, Koeffler HP.
    Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals.
    Leukemia 22, 1773-1778 (2008)

  52. Fukamachi H, Mimata A, Tanaka I, Ito K, Ito Y, Yuasa Y.
    Differentiation in vitro of Runx3-/-p53-/- gastric epithelial cells into intestinal type cells.
    Cancer Science 99, 671-676 (2008)

ページのトップへ戻る